FLAME 2020
Lysosomal Disease Treatments: Technologies and Global Markets
Report Highlights
The global market for lysosomal storage diseases treatment should grow from $5.1 billion in 2018 to reach $7.6 billion by 2023 at a compound annual growth rate (CAGR) of 8.3% for the period of 2018-2023.
Report Includes
- 37 data tables and 25 additional tables
- An overview of the global market for lysosomal disease treatments
- Analyses of global market trends, with data from 2017, estimates for 2018 and projections of compound annual growth rates (CAGRs) through 2023
- Segmentation of the global market by cancer therapy indiscation, treatment type, route of administration, end-use, application and geographical region
- Information on current regulatory environment, and a trend analysis of recent government policies and regulations for lysosomal disease treatments
- Assessment of lysosomal storage diseases by the accumulated substrate and the profitability of focusing on ultra-orphan diseases
- Profiles of major players in the industry, including Astellas Pharma, Astrazeneca, Eli Lilly and Co., Merck & Co., Inc., and Novo Nordisk A/S
Report Scope
The lysosomal storage disease treatment market has been divided by type of indication into: Gaucher’s Diseases, Fabry Diseases, Pompe’s Syndrome, Mucopolysaccharidosis and more. Mucopolysaccharidosis is further segmented into Hunter syndrome, Hurlers Syndrome and Moriquo syndrome. The market is also segmented by routing of administration into IV and oral. The market has been divided into hospitals, clinics and other facilities into end users by type of treatment into enzyme replacement therapy and substrate reduction therapy. The market has been segmented into North America, Europe, Asia-Pacific and RoW.
Analyst Credentials
Neha Maliwal is a graduate in biotechnology with an MBA in Marketing from Pune University in India. With more than five years of experience in the market research industry, she has worked as a business analyst across various industries, such as healthcare IT and the U.S. mortgage industry. She has authored many BCC Research reports, with topics including healthcare analytics, antibiotics and sample preparation.
